Orphazyme seeks court protection during restructuring

The biotech company hopes that restructuring will mean that its operations can continue, at least to some degree, paid for through a fundraising round, sale of its assets or a combination of the two.
Photo: Orphazyme / PR
Photo: Orphazyme / PR
by marketwire, translated by catherine brett

Danish biotech company Orphazyme has applied for legally binding protection from its creditors while it restructures.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading